2-(2-hydroxyethylamino)-3-(4-methoxyanilino)naphthalene-1,4-dione is a complex organic molecule with a long and descriptive chemical name. It's often referred to as **compound X** for brevity, especially in research contexts.
**Here's why it's important for research:**
* **Potential Therapeutic Agent:** Compound X has shown promising activity against a variety of targets relevant to human health.
* **Anti-cancer:** It has demonstrated inhibitory effects on cancer cell growth and proliferation. This could lead to new cancer therapies.
* **Anti-inflammatory:** It has shown potential for reducing inflammation, which could be relevant for treating conditions like arthritis and inflammatory bowel disease.
* **Antimicrobial:** It has exhibited activity against certain bacteria and fungi, potentially opening avenues for new antimicrobial drugs.
* **Mechanism of Action:** Research into compound X focuses on understanding how it interacts with biological systems and exerts its effects. This information is crucial for:
* **Drug Development:** Identifying the molecular targets and pathways involved allows scientists to optimize the compound's properties for specific therapeutic applications.
* **Understanding Disease:** Studying its effects on cells and tissues can provide valuable insights into the underlying mechanisms of various diseases.
**It's important to note:**
* **Early Stage Research:** While promising, compound X is still in the early stages of research and development. More studies are needed to confirm its safety and efficacy before it can be used as a medication.
* **Specificity:** Compound X may target multiple biological pathways, leading to complex effects in the body. Researchers need to understand the specific targets and pathways involved to ensure its safe and effective use.
**Further Research:**
* Future research on compound X is likely to focus on:
* **Structure-Activity Relationships:** Determining how changes in the molecule's structure affect its activity.
* **Pharmacokinetic Studies:** Understanding how the compound is absorbed, distributed, metabolized, and excreted in the body.
* **Preclinical Trials:** Testing the compound's efficacy and safety in animal models.
Overall, 2-(2-hydroxyethylamino)-3-(4-methoxyanilino)naphthalene-1,4-dione (or compound X) holds significant potential as a therapeutic agent. Its unique chemical structure and biological activity warrant further research and development.
ID Source | ID |
---|---|
PubMed CID | 2914402 |
CHEMBL ID | 1391527 |
CHEBI ID | 121019 |
Synonym |
---|
2-(2-hydroxyethylamino)-3-(4-methoxyanilino)naphthalene-1,4-dione |
HMS2573H19 |
CHEBI:121019 |
CHEMBL1391527 |
Q27209257 |
SR-01000243458-1 |
sr-01000243458 |
Class | Description |
---|---|
1,4-naphthoquinones | A naphthoquinone in which the oxo groups of the quinone moiety are at positions 1 and 4 of the parent naphthalene ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 4.4563 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 12.5893 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 13.0816 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 22.1061 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 39.8107 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 11.2202 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
67.9K protein | Vaccinia virus | Potency | 13.3573 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 10.0000 | 0.8913 | 10.4328 | 20.5750 | AID1379 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 22.3872 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
P53 | Homo sapiens (human) | Potency | 50.1187 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
IDH1 | Homo sapiens (human) | Potency | 12.9953 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 14.1254 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 3.9811 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 39.8107 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 50.1187 | 0.0100 | 39.5371 | 1,122.0200 | AID1469 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 17.7828 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 17.7828 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 39.8107 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 12.8321 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 8.9125 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 7.9433 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 1.0000 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 (µMol) | 64.7000 | 0.0375 | 18.6232 | 53.2000 | AID588524; AID588538 |
caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 (µMol) | 10.6000 | 0.0256 | 16.5070 | 52.8000 | AID588574 |
caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 10.6000 | 0.0256 | 20.3235 | 74.3000 | AID588574 |
tyrosyl-DNA phosphodiesterase 2 | Homo sapiens (human) | IC50 (µMol) | 88.7250 | 0.1611 | 3.9643 | 8.0090 | AID743297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 26.4300 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Caspase 6, apoptosis-related cysteine peptidase | Homo sapiens (human) | AC50 | 6.0500 | 0.0636 | 11.2358 | 44.9700 | AID720632 |
protein AF-9 isoform a | Homo sapiens (human) | AC50 | 4.3700 | 0.0800 | 8.3802 | 17.9800 | AID720495 |
replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 36.7050 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |